A global consensus meeting was convened to go over current evidence and knowledge gaps and propose collaborative studies on population-wide screening and eradication of Helicobacter pylori for the prevention of gastric cancer (GC).
A review of relevant literature looked at the relationship between obstructive sleep apnea and adverse COVID-19 outcomes.
Therapies for the treatment of inflammatory bowel disease may have a potential use in patients with COVID-19.
Recruitment has begun for study examining the efficacy of canakinumab for the treatment of patients with COVID-19 and acute myocardial injury.
In a population-based study, risk for early-onset neonatal bacterial sepsis among newborns increased with maternal body mass index.
A retrospective study of CMV-seropositive adults receiving allogeneic HCT and CMV-seronegative HLA-matched sibling donors found that vancomycin exposure before HCT increased the risk for CMV reactivation.
Researchers observed the presence of acute liver injury caused by COVID-19 in patients at multiple hospitals in China.
Fecal microbiota transplant (FMT) appears safe in decolonizing multi-drug resistant organisms (MDRO) from intestinal reservoirs in affected patients, even those who are highly immunosuppressed.
Patients with IBD should not alter their treatment during the COVID-19 pandemic; however, starting a new treatment regimen should be avoided.
A novel rifabutin-based therapy (RHB-105) may be a potential first-line defense against Helicobacter pylori (H. pylori) infection.
